ACE Inhibitor and Calcium Channel Blocker Combination Therapy

Benefits of ACE Inhibitor + CCB Combination

• The combination of an ACE inhibitor and a CCB provides complementary mechanisms of action, resulting in additive blood pressure lowering effects, as recommended by major guidelines, including the American College of Cardiology and the European Society of Cardiology 1, 4
• The American College of Cardiology and the European Society of Cardiology recommend this combination as one of the preferred combinations for hypertension management, due to its effectiveness in reducing cardiovascular events 5, 6
• ACE inhibitor + CCB combinations have been shown to reduce cardiovascular events more effectively than some other combinations, with a synergistic effect on blood pressure control 3, 7
• Fixed-dose combinations (single pills containing both medications) are available and can improve medication adherence, as suggested by the European Heart Journal 3

Mechanism and Rationale

• When used together, ACE inhibitors and CCBs target different blood pressure control systems, creating a synergistic effect, as described in the Circulation journal 1

Clinical Evidence Supporting This Combination

• The European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines specifically recommend ACE inhibitor + CCB as an initial combination therapy for most hypertensive patients, due to its effectiveness and safety profile 5

Important Considerations

• Dihydropyridine CCBs (like amlodipine) are most commonly combined with ACE inhibitors, while non-dihydropyridine CCBs (like verapamil, diltiazem) can also be used with ACE inhibitors, though they have different side effect profiles, as noted by the Journal of the American College of Cardiology 8
• Blood pressure should be monitored after starting this combination, especially during the first month of therapy, as recommended by the American College of Cardiology 5

What to Avoid

• The American College of Cardiology recommends avoiding the combination of an ACE inhibitor with an angiotensin receptor blocker (ARB) or direct renin inhibitor, as this combination increases cardiovascular and renal risk 1, 4
• The Journal of the American College of Cardiology advises against abrupt discontinuation of either medication, due to potential rebound effects 8

Special Populations

• The American Diabetes Association and the American College of Cardiology recommend this combination for patients with diabetes, chronic kidney disease with albuminuria, or high cardiovascular risk, due to its effectiveness in reducing cardiovascular events 5, 9
• The Journal of the American College of Cardiology suggests that this combination is appropriate for Black patients after initial therapy, and for elderly patients, but with careful monitoring and dose adjustment 5, 6